FY2025 · ended Dec 31, 2025 · Revenue $1.94B, -39.9% YoY · Filed Feb 20, 2026
Moderna, Inc. (MRNA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.9 billion and a net loss of $2.8 billion. Free cash flow was -$2.1 billion. As of Jun 30, 2026 it held $6.9 billion in cash and investments and $1.3 billion in total debt.
Revenue (TTM)
$2.23B
-27.6% vs year-ago TTM
Net income (TTM)
$-3.15B
-8.5% vs year-ago TTM
Operating cash flow (TTM)
$-1.07B
+60.2% vs year-ago TTM
Free cash flow (TTM)
$-1.24B
+64.4% vs year-ago TTM
EPS (TTM)
$-8.01
-6.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
394.94M
+2.4% vs prior year
Net cash
$5.62B
as of Jun 30, 2026
Operating margin
-149.0%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MRNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1682852
- Former names
- Moderna Therapeutics, Inc. (until Aug 24, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.9B | $3.2B | $6.8B | $19.3B | $18.5B |
| Operating income | -$3.1B | -$3.9B | -$4.2B | $9.4B | $13.3B |
| Net income | -$2.8B | -$3.6B | -$4.7B | $8.4B | $12.2B |
| Diluted EPS | -$7.26 | -$9.28 | -$12.33 | $20.12 | $28.29 |
| Operating cash flow | -$1.9B | -$3.0B | -$3.1B | $5.0B | $13.6B |
| Free cash flow | -$2.1B | -$4.1B | -$3.8B | $4.6B | $13.3B |
| Total assets | $12.3B | $14.1B | $18.4B | $25.9B | $24.7B |
| Total liabilities | $3.7B | $3.2B | $4.6B | $6.7B | $10.5B |
| Stockholders' equity | $8.7B | $10.9B | $13.9B | $19.1B | $14.1B |
| Cash and investments | $8.1B | $9.5B | $13.3B | $18.2B | $17.6B |
| Total debt | $1.3B | $747.0M | $1.2B | $1.2B | $916.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 1, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 8, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 11, 2026 | May 6, 2026 |
All 1001 Moderna, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.